AU6664190A - Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen - Google Patents
Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigenInfo
- Publication number
- AU6664190A AU6664190A AU66641/90A AU6664190A AU6664190A AU 6664190 A AU6664190 A AU 6664190A AU 66641/90 A AU66641/90 A AU 66641/90A AU 6664190 A AU6664190 A AU 6664190A AU 6664190 A AU6664190 A AU 6664190A
- Authority
- AU
- Australia
- Prior art keywords
- human
- specificity
- antibody
- tumor cell
- cell antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43501289A | 1989-11-13 | 1989-11-13 | |
US435012 | 1989-11-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU6664190A true AU6664190A (en) | 1991-05-23 |
AU634314B2 AU634314B2 (en) | 1993-02-18 |
Family
ID=23726623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU66641/90A Ceased AU634314B2 (en) | 1989-11-13 | 1990-11-13 | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0457875A4 (en) |
JP (1) | JPH03206886A (en) |
KR (1) | KR910009284A (en) |
AU (1) | AU634314B2 (en) |
CA (1) | CA2044590A1 (en) |
WO (1) | WO1991007418A1 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
US5641751A (en) * | 1995-05-01 | 1997-06-24 | Centocor, Inc. | Tumor necrosis factor inhibitors |
WO1997037690A2 (en) * | 1996-04-10 | 1997-10-16 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
IT1289608B1 (en) * | 1997-02-05 | 1998-10-15 | Angelini Ricerche Spa | COMPOSITION FOR THERAPEUTIC OR DIAGNOSTIC USE ADMINISTRABLE VIA INTRANASAL, SUBLINGUAL OR VAGINAL |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
US7033594B2 (en) | 2000-03-31 | 2006-04-25 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
WO2003062370A2 (en) | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
CA2484640C (en) | 2002-05-15 | 2012-01-17 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
JP5576007B2 (en) | 2003-01-27 | 2014-08-20 | エンドサイト・インコーポレイテッド | Vitamin receptor binding drug delivery conjugates |
US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US20080280937A1 (en) | 2005-08-19 | 2008-11-13 | Christopher Paul Leamon | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives |
KR20130113543A (en) | 2005-08-19 | 2013-10-15 | 엔도사이트, 인코포레이티드 | Multi-drug ligand conjugates |
WO2007092299A2 (en) | 2006-02-03 | 2007-08-16 | Purdue Research Foundation | Targeted conjugates and radiation |
US9555139B2 (en) | 2007-03-14 | 2017-01-31 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
US9138484B2 (en) | 2007-06-25 | 2015-09-22 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
SI2187965T1 (en) | 2007-08-17 | 2020-03-31 | Purdue Research Foundation Office Of Technology Commercialization | Psma binding ligand-linker conjugates and methods for using |
US9187521B2 (en) | 2007-10-25 | 2015-11-17 | Endocyte, Inc. | Tubulysins and processes for preparing |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
JP2014530360A (en) | 2011-10-07 | 2014-11-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | OxMIF as a diagnostic marker |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
EP2908818A4 (en) | 2012-10-16 | 2016-07-13 | Endocyte Inc | Drug delivery conjugates containing unnatural amino acids and methods for using |
EP2919774A4 (en) | 2012-11-15 | 2016-11-09 | Endocyte Inc | Conjugates for treating diseases caused by psma expressing cells |
MY194484A (en) | 2013-10-18 | 2022-11-30 | Deutsches Krebsforsch | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
WO2016148674A1 (en) | 2015-03-13 | 2016-09-22 | Endocyte, Inc. | Conjugates for treating diseases |
AR125353A1 (en) | 2021-04-16 | 2023-07-12 | Novartis Ag | RADIOTHERAPEUTIC AGENTS DIRECTED TO THE FOLATE RECEPTOR AND THEIR USE |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8800078D0 (en) * | 1988-01-05 | 1988-02-10 | Ciba Geigy Ag | Novel antibodies |
AU625613B2 (en) * | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
IL89489A0 (en) * | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
-
1990
- 1990-11-13 WO PCT/US1990/006620 patent/WO1991007418A1/en not_active Application Discontinuation
- 1990-11-13 CA CA002044590A patent/CA2044590A1/en not_active Abandoned
- 1990-11-13 JP JP2308453A patent/JPH03206886A/en active Pending
- 1990-11-13 AU AU66641/90A patent/AU634314B2/en not_active Ceased
- 1990-11-13 EP EP19910900650 patent/EP0457875A4/en not_active Withdrawn
- 1990-11-13 KR KR1019900018568A patent/KR910009284A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU634314B2 (en) | 1993-02-18 |
KR910009284A (en) | 1991-06-28 |
EP0457875A1 (en) | 1991-11-27 |
EP0457875A4 (en) | 1993-03-03 |
WO1991007418A1 (en) | 1991-05-30 |
CA2044590A1 (en) | 1991-05-14 |
JPH03206886A (en) | 1991-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6664190A (en) | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen | |
AU1085488A (en) | Monoclonal antibodies to a pan-malarial antigen | |
AU4725485A (en) | Monoclonal antibody to a human carcinoma tumor associated antigen | |
OA09734A (en) | Chimeric antibody with specificity to human B cell surface antigen. | |
GR900100221A (en) | Novel monoclonic antibodies against a new antigen relating to human tumours | |
AU3107289A (en) | Chimeric antibodies directed against human carcinoembryonic antigen | |
AU5141193A (en) | Monoclonal antibodies to prostate cells | |
AU625613B2 (en) | Novel chimeric antibodies | |
ZA884651B (en) | Monoclonal antibody specific to hiv antigens | |
GB8800077D0 (en) | Novel chimeric antibodies | |
ZA887771B (en) | Monoclonal antibody specific to a novel epitope of the lfa-1 antigen of human t lymphocytes | |
AU627591B2 (en) | Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen | |
ZA852426B (en) | Monoclonal antibody specific for human basal cell surface antigen | |
AU6663990A (en) | Chimeric mouse-human antibodies with specificity to hiv antigens | |
AU6036690A (en) | Human monoclonal antibodies to hiv-1mn gp 120 | |
EP0460607A3 (en) | Novel monoclonal antibody to novel antigen associated with human tumors | |
EP0159025A3 (en) | Monoclonal antibody specific to human alpha2-plasmin | |
AU7912887A (en) | Monoclonal antibodies to fibrin | |
AU4450389A (en) | Anti-fucosylcermiade monoclonal antibody | |
AU569816B2 (en) | Monoclonal anti-alpha-amylase antibody | |
AU4407989A (en) | Monoclonal antibody specific to a novel mucin-like glycoprotein antigen on human carcinoma cells | |
AU4070685A (en) | Monoclonal antibody specific for human basal cell surfaces | |
AU3812485A (en) | Monoclonal antibody to activated macrophages | |
AU6609686A (en) | Detection of human cancer with a monoclonal antibody specific for antigen 9p650 | |
AU620330B2 (en) | Immunodiagnostic assays using chimeric antigens |